Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background & Aims</h3><p>IL-17A-producing T cells are present in autoimmune cholestatic liver diseases; however, little is known about the contribution of IL-17 to periductal immune responses. Here we investigated the role of IL-17 produced by antigen specific CD8<sup>+</sup> T cells in a mouse model of cholangitis and <em>in vitro</em> in human cholangiocyte organoids.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>K14-OVAp mice express a MHC I restricted ovalbumin peptide sequence (SIINFEKL) on cholangiocytes. Cholangitis was induced by the adoptive transfer of transgenic OVA-specific OT-1 CD8<sup>+</sup> T cells that either had OT-1<sup>wt</sup> or lacked IL-17A/F (OT-1<sup>IL17ko</sup>). The response of mouse and human cholangiocytes/organoids to IL-17A was assessed <em>in vitro</em>.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Transfer of OVA-specific OT-1<sup>IL17ko</sup> cells significantly aggravated periductal inflammation in K14-OVAp recipient mice, compared to transfer of OT-1<sup>wt</sup> T cells. OT-1<sup>IL17ko</sup> T cells were highly activated in the liver and displayed increased cytotoxicity and proliferation. IL-17A/F produced by transferred OT-1<sup>wt</sup> CD8<sup>+</sup> T cells induced upregulation of the inhibitory molecule PD-L1 on cholangiocytes, restricting cholangitis by limiting cytotoxicity and proliferation of transferred cells. In contrast, OT-1<sup>IL17ko</sup> T cells failed to induce PD-L1 on cholangiocytes, resulting in uncontrolled expansion of cytotoxic CD8<sup>+</sup> T cells and aggravated cholangitis. Blockade of PD-L1 after transfer of OT-1<sup>wt</sup> T cells with anti-PD-L1 antibody also resulted in aggravated cholangitis. Using human cholangiocyte organoids, we were able to confirm that IL-17A induces PD-L1 expression in cholangiocytes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>We demonstrate an important function of IL-17 in restricting cholangitis and protecting from CD8<sup>+</sup> T cell mediated inflammatory bile duct injury that was mediated by upregulation of PD-L1 on cholangiocytes. Targeting of IL-17, which is an effective treatment for several autoimmune diseases, for the treatment of cholangitis should be undertaken with caution.</p>

IL-17A/F Enable Cholangiocytes to Restrict T Cell-Driven Experimental Cholangitis Via PD-1/PD-L1 Interaction

IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression

IL-17 Imbalance Promotes the Pyroptosis in Immune-Mediated Liver Injury Through STAT3-IFI16 Axis.

IL-17A produced by invariant natural killer T cells and CD3(+)CD56(+)alpha Galcer-CD1d tetramer(-) T cells promote liver fibrosis in patients with primary biliary cholangitis

IL-17A produced by invariant natural killer T cells and CD3+CD56+αGalcer-CD1d tetramer– T cells promote liver fibrosis in patients with primary biliary cholangitis

Differential modulation by IL-17A of Cholangitis versus Colitis in IL-2Rα deleted mice.

Lamina Propria Interleukin 17 A Aggravates Natural Killer T-cell Activation in Autoimmune Hepatitis

Deletion of Interleukin-12p40 Suppresses Autoimmune Cholangitis in Dominant Negative Transforming Growth Factor Beta Receptor Type Ii Mice

The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice.

Targeting pathogenic CD8+ tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis

Hepatic IL-17 responses in human and murine primary biliary cirrhosis

Therapeutic Potential of The Low-dose IL-2 Through Targeting the Th17/Treg Axis in Primary Biliary Cholangitis Mice

Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells.

Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases

Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Rα−/− mice

Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha(-/-) mice.

Interleukin 23 Produced by Hepatic Monocyte-Derived Macrophages Is Essential for the Development of Murine Primary Biliary Cholangitis

The Proinflammatory Cytokines IL-18, IL-21, and IFN-γ Differentially Regulate Liver Inflammation and Anti-Mitochondrial Antibody Level in a Murine Model of Primary Biliary Cholangitis

IL-12/Th1 and IL-23/Th17 Biliary Microenvironment in Primary Biliary Cirrhosis: Implications for Therapy

The effects of low-dose IL-2 on Th17/Treg cell imbalance in primary biliary cholangitis mouse models

Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression